 |
市場調查報告書
商品編碼
1427218
全球細胞增殖市場規模、佔有率、成長分析、按產品、按細胞類型 - 產業預測 2023-2030Global Cell Expansion Market Size, Share, Growth Analysis, By Product(Consumables, Culture Flasks & Accessories), By Cell Type(Mammalian, Microbial) - Industry Forecast 2023-2030 |
||||||
2022年全球細胞增殖市場規模為252.1億美元，從2023年的276億美元擴大到2031年的570.6億美元，複合年成長率預計將成長9.5%。
市場促進因素之一是擴大採用自動化解決方案，特別是在細胞增殖應用中，例如基因療法、細胞療法產品 (CTP) 和其他生技藥品，以提高程序的可靠性。這會導致成本和勞動力的增加節省開支的同時提高生產力。在CTP 生產中轉向一次性系統(SUS) 消除了由於滅菌不充分而導致的交叉污染和培養物污染的風險，從而實現長期成本節約並以更高的細胞密度生產CTP，從而提供了顯著的製造優勢。 SUS 採用率的快速成長將刺激 CTP 的發展並進一步促進市場擴張。同時，在商業和公共組織資金增加以及加速舉措進展的措施的推動下，生命科學領域對細胞療法的興趣日益濃厚。國際幹細胞研究學會等組織正積極為幹細胞相關研究應用尋求資金，確保細胞增殖的技術進步和產品創新為市場帶來重大經濟機遇，有望帶來成功。然而，缺乏先進設備和3D細胞擴增技術可能成為市場擴張的障礙。
使用自上而下和自下而上的方法來估計和檢驗全球細胞增殖市場的規模，並估計其他各個相關子市場的規模。用於估計市場規模的調查方法包括以下細節：二級研究用於確定市場中的主要企業，一級和二級研究用於確定每個地區的市場佔有率。整個過程包括研究主要企業的年度和財務報告以及廣泛的採訪，以獲得執行長、副總裁、董事和行銷負責人等行業領導者的重要見解。所有股份比率和細分均使用二手資訊確定並使用主要資訊檢驗。本研究涵蓋的所有可能影響市場的參數都經過廣泛而詳細的考慮，透過初步研究檢驗並進行分析，以獲得最終的定量和定性資料。
細胞增殖全球細分市場分析
全球細胞增殖市場根據產品、最終用途、細胞類型和地區進行細分。依產品分類，市場分為消耗品、培養瓶及配件、儀器。依最終用途，市場分為生物製藥、研究機構、細胞庫等。依細胞類型，市場分為哺乳動物、微生物和其他。依地區分類，分為北美、歐洲、亞太地區、中東/非洲、拉丁美洲。
全球細胞增殖市場的促進因素
CRISPR/Cas9 等基因工程的進步簡化了為高效蛋白質表現而客製化的優質細胞株的創建。這些尖端工具能夠精確調整細胞基因組、提高蛋白質產量、完善細胞製程並提高產品標準。仔細表徵和高產細胞株的存在是擴大細胞表現領域的主要驅動力。
全球細胞增殖市場的限制因素
表達系統細胞株的產生通常依賴動物或人類來源的細胞，導致倫理困境。圍繞動物福利、人類細胞的道德來源以及胚胎幹細胞的使用的擔憂可能會限制某些細胞株的獲取和接受。這種倫理考慮可能會阻礙進展並限制細胞表達系統的選擇。
全球細胞增殖市場趨勢
研究人員和科學家正在積極研究和開發創新的表現系統，作為解決傳統平台所帶來的限制的手段。特別是，人們對無細胞表現系統越來越感興趣，例如無細胞蛋白質合成（CFPS），其具有不依賴完整細胞即可產生蛋白質的優勢。此外，合成生物學技術被用來增強工程細胞株的表達能力並最佳化蛋白質生產效率。
目錄
- 執行摘要
- 調查方法
- 母市場分析
- 主要市場考察
- 技術分析
- 價格分析
- 供應鏈分析
- 價值鏈分析
- 市場生態系統
- 智慧財產權分析
- 貿易分析
- Start-Ups分析
- 原料分析
- 創新矩陣
- 研發線產品分析
- 總體經濟指標
- 主要投資分析
- 關鍵成功因素
- 競爭程度
- 市場動態及展望
- 市場動態
- 促進因素
- 機會
- 抑制因素
- 任務
- 監管形勢
- 波特的分析
- 對未來中斷的特殊考慮
- 市場動態
- 全球細胞增生市場：按產品
- 市場概況
- 消耗品
- 培養瓶及配件
- 裝置
- 全球細胞增生市場：依細胞類型
- 市場概況
- 哺乳動物的
- 微生物
- 其他
- 全球細胞增生市場規模：按地區
- 市場概況
- 北美洲
- 美國
- 加拿大
- 歐洲
- 德國
- 西班牙
- 法國
- 英國
- 其他歐洲國家地區
- 亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
- 拉丁美洲
- 巴西
- 其他拉丁美洲地區
- 中東和非洲 (MEA)
- 海灣合作理事會國家
- 南非
- 其他中東/非洲地區
- 競爭形勢
- 前5名企業對比
- 主要企業市場定位（2021年）
- 主要市場參與者所採取的策略
- 關鍵成功策略
- 近期市集活動
- 主要企業市場佔有率（2021年）
- 主要企業簡介
- Thermo Fisher Scientific Inc.（United States）
- Merck KGaA（Germany）
- Lonza Group Ltd.（Switzerland）
- GE Healthcare（United States）
- Sartorius AG（Germany）
- Promega Corporation（United States）
- Agilent Technologies, Inc.（United States）
- Bio-Rad Laboratories, Inc.（United States）
- Eppendorf AG（Germany）
- Takara Bio Inc.（Japan）
- GenScript Biotech Corporation（China）
- CellGenix GmbH（Germany）
- BD Biosciences（United States）
- Novasep Holding SAS（France）
- OriGene Technologies, Inc.（United States）
- Lonza Biologics Plc（United Kingdom）
- Danaher Corporation（United States）
- Wuxi AppTec Co., Ltd.（China）
- Charles River Laboratories International, Inc.（United States）
- Miltenyi Biotec GmbH（Germany）
- New England Biolabs, Inc.（United States）
- Qiagen NV（Netherlands）
Global Cell Expansion Market size was valued at USD 25.21 billion in 2022 and is poised to grow from USD 27.60 billion in 2023 to USD 57.06 billion by 2031, growing at a CAGR of 9.5% during the forecast period (2024-2031).
One of the key drivers in the market stems from the increasing adoption of automated solutions in cell expansion applications, particularly in gene treatments, cell therapy products (CTP), and other biologics, resulting in cost and labor savings while enhancing procedural reliability. The shift towards Single-Use Systems (SUS) in CTP manufacturing brings significant production advantages by eliminating risks of cross-contamination and culture contamination due to inadequate sterilization, leading to long-term cost reductions and enabling the production of CTP with higher cell densities. This surge in SUS adoption stimulates the development of CTP, further propelling market expansion. Concurrently, the life sciences sector experiences a rising interest in cellular therapies, driven by augmented funding from commercial and public entities, along with their initiatives to foster cellular therapy advancements. Entities like the International Society for Stem Cell Research actively seek funding opportunities for stem cell-related research applications, anticipating substantial financial success for the market fueled by technological advancements and product innovations in cell expansion. However, a potential obstacle to market progression may arise from the scarcity of advanced instrumentation and 3D cell expansion technology.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cell Expansion Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Cell Expansion Market Segmental Analysis
Global Cell Expansion Market is segmented on the basis of product, end use, cell type and region. By product, the market is segmented into consumables, culture flasks & accessories, instruments. By end use, market is segmented into biopharmaceuticals, research institutions, cell banks, others. By cell type, the market is segmented into mammalian, microbial, others. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
Drivers of the Global Cell Expansion Market
The ongoing progress in genetic engineering, notably exemplified by CRISPR/Cas9, has streamlined the creation of superior cell lines tailored for efficient protein expression. These cutting-edge tools empower exact adjustments to cell genomes, enhancing protein yields, refining cellular processes, and elevating product standards. The existence of meticulously characterized and exceptionally productive cell lines significantly bolsters the expansion of the cell expression sector.
Restraints in the Global Cell Expansion Market
The creation of cell lines for expression systems frequently relies on animal or human-derived cells, leading to ethical dilemmas. Concerns over animal rights, ethically sourcing human cells, and the use of embryonic stem cells can constrain the accessibility and acceptance of specific cell lines. These ethical considerations have the potential to impede advancement and narrow the options for cell expression systems.
Market Trends of the Global Cell Expansion Market
Researchers and scientists are actively investigating and advancing innovative expression systems as a means to address the constraints posed by conventional platforms. Notably, there is a growing interest in cell-free expression systems such as cell-free protein synthesis (CFPS), which offer the advantage of protein production without reliance on intact cells. Furthermore, synthetic biology techniques are being utilized to enhance expression capacities and optimize protein production efficiency in engineered cell lines.
Table of Contents
- Executive Summary
- Market Overview
- Wheel of Fortune
- Research Methodology
- Information Procurement
- Secondary & Primary Data Sources
- Market Size Estimation
- Market Assumptions & Limitations
- Parent Market Analysis
- Market Overview
- Market Size
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
- Key Market Insights
- Technology Analysis
- Pricing Analysis
- Supply Chain Analysis
- Value Chain Analysis
- Ecosystem of the Market
- IP Analysis
- Trade Analysis
- Startup Analysis
- Raw Material Analysis
- Innovation Matrix
- Pipeline Product Analysis
- Macroeconomic Indicators
- Top Investment Analysis
- Key Success Factor
- Degree of Competition
- Market Dynamics & Outlook
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
- Regulatory Landscape
- Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
- Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
- Market Dynamics
- Global Cell Expansion Market by Product
- Market Overview
- Consumables
- Culture Flasks & Accessories
- Instruments
- Global Cell Expansion Market by Cell Type
- Market Overview
- Mammalian
- Microbial
- Others
- Global Cell Expansion Market Size by Region
- Market Overview
- North America
- USA
- Canada
- Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA
- Competitive Landscape
- Top 5 Player Comparison
- Market Positioning of Key Players, 2021
- Strategies Adopted by Key Market Players
- Top Winning Strategies
- By Development
- By Company
- By Year
- Recent Activities in the Market
- Key Companies Market Share (%), 2021
- Key Company Profiles
- Thermo Fisher Scientific Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck KGaA (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Lonza Group Ltd. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GE Healthcare (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sartorius AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Promega Corporation (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Agilent Technologies, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bio-Rad Laboratories, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eppendorf AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Takara Bio Inc. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GenScript Biotech Corporation (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- CellGenix GmbH (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- BD Biosciences (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novasep Holding S.A.S. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- OriGene Technologies, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Lonza Biologics Plc (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Danaher Corporation (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Wuxi AppTec Co., Ltd. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Charles River Laboratories International, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Miltenyi Biotec GmbH (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- New England Biolabs, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Qiagen N.V. (Netherlands)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Thermo Fisher Scientific Inc. (United States)
